1. Academic Validation
  2. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus

Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus

  • Antiviral Res. 2018 Sep;157:128-133. doi: 10.1016/j.antiviral.2018.07.013.
Sunwen Chou 1 Ronald J Ercolani 2 Katayoun Derakhchan 3
Affiliations

Affiliations

  • 1 Division of Infectious Diseases, Oregon Health & Science University, USA; Portland Veterans Affairs Health Care System, OR USA. Electronic address: [email protected].
  • 2 Portland Veterans Affairs Health Care System, OR USA.
  • 3 Global Nonclinical Development, Shire Pharmaceuticals, Cambridge, MA USA.
Abstract

The human cytomegalovirus (CMV) UL97 kinase inhibitor maribavir is in Phase III clinical trials as Antiviral therapy, including use for infections refractory or resistant to standard therapy. To assess its activity in combination with approved and experimental CMV antivirals, and with the mTOR Inhibitor rapamycin (sirolimus), drug effects were tested by in vitro checkerboard assays and the data were analyzed using a three dimensional model based on an independent effects definition of additive interactions. Baseline virus and representative drug-resistant mutants were tested. According to the volume of synergy at 95% confidence, maribavir showed additive interactions with foscarnet, cidofovir, letermovir and GW275175X when tested against wild type and mutant viruses, strong antagonism with ganciclovir, and strong synergy with rapamycin, the latter suggesting a potentially useful therapeutic combination.

Keywords

Antagonism; Cytomegalovirus; Ganciclovir; Maribavir; Sirolimus; Synergism.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15233
    99.38%, CMV Inhibitor
    CMV